

Title

Clinical characteristics of children with COVID-19 admitted in a tertiary referral center in Perú

Authors

Christian Chiara Chilet¹
Medalit Luna Vilchez¹
Julio Maquera Afaray¹
Blanca Salazar Mesones¹
Diana Portillo Alvarez¹
Ramiro Priale Miranda¹
Franklin Mendoza¹
Aldo Munayco¹
Jenny Baca²
Mitsi Santiago²
Jose W. López^{1,3}

Institutional affiliations

¹Unidad de Atención Integral Especializada, Instituto Nacional de Salud del Niño San

Borja, Lima, Perú.

²Coordinación Técnica de Epidemiología, Instituto Nacional de Salud del Niño San

Borja, Lima, Perú.

³Facultad de Ciencias de la Salud, Universidad Científica del Sur, Lima, Perú

Corresponding author

Name: Jose Wagner Lopez Revilla

Address: Carr. Panamericana Sur 19, Villa EL Salvador 15067

Email: jlopezre@cientifica.edu.pe

Phone: (511) 610 6400

Author contributions

C.Ch., M.L, J.M., B.S., D.P., R.P., F.M., A.M, and J.W.L conceived the study. C.Ch., M.L, J.M., B.S., D.P., R.P., J.B., M.S. and J.W.L collected the data. C.Ch., J.W.L and M.L.performed statistical analysis and figure generation. All authors reviewed the manuscript.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Funding

The study has been funded through the research incentive processes of the Instituto Nacional de Salud del Niño San Borja

Conflicts of interest

The authors declare no conflict of interest.

Title: Clinical characteristics of children with COVID-19 admitted in a tertiary referral center in Perú

Abstract

Introduction

COVID-19 pandemic represents a big impact on children's health, this study describes the behavior of the disease in hospitalized pediatric patients in the Instituto Nacional de Salud del Niño San Borja (INSN-SB).

Methods

Retrospective study of patients with confirmed COVID-19 diagnostic between March and July 2020. Demographic, clinic, laboratory, radiology and treatment data were collected and for the analysis descriptive statistics were included.

Results

From a total of 91 patients. 36.3% (33) were female. The age group who was affected the most were school children with a median age of 4 years old (IQR 1-8). Patients who came from Lima represented 61.5%. Previous contact was determined in 30.8% of the cases. PCR results for SARS CoV-2 were positive in 50.6% of the cases and 49.4% in the quick tests. Comorbidity was present in 53.8% of the cases. Most frequent symptoms were fever (39.6%), general discomfort (23.1%), cough (19.8%) and shortness of breath (14.3%). Presence of MIS-C was confirmed in 6 patients. Use of antibiotics represented 76.9% of the cases. The most frequent radiology pattern was bilateral interstitial (57.7%). Comorbidities were present in 68.2% (15/22) of patients in PICU. From a total of 9 deceased patients, 6 were admitted in PICU and 8 presented associated comorbidities.

Conclusions

COVID-19 in children displays mild and moderate clinical manifestations. A great proportion of patients exhibited comorbidities, especially PICU patients and the ones that died.

Key words: COVID-19, children, comorbidities

What is known about the subject:

In pediatric patients, the prevalence and severity of COVID-19 are usually low, however, in the presence of MIS-C, greater severity and probability of admission to the PICU is observed.

What this study adds

- This study describes the results of complex pediatric patients and the associated comorbidity in LMIC setting that showed greater severity and admission to the ICU.
- Microbiological isolates in cultures were low, therefore the initiation of empirical antibiotic therapy is not justified in most cases.

Introduction

The new Coronavirus pandemic is the biggest public health crisis which the world still faces. It has been estimated that 90% of the cases correspond to the adult population and only between the 1% and 5% to the pediatric population (1), from which more than 90% are asymptomatic forms of presentation, mild or moderate and only 5.9% are severe (2), a smaller percentage compared with the severity reported in adults which is from 12.6% to 23.5% (3). It has been reported that from 48 pediatric patients admitted to PICU (pediatric intensive care unit), 40 (83%) had some comorbidity (4). Another study reported that from 651 children, 276 (46%) had at least one comorbidity (6).

Furthermore, the presence of pediatric multisystem inflammatory syndrome (MIS-C) has been documented which can be severe and present itself with significant cardiovascular compromise (5). It has been reported that patients with MIS-C presented 5 times higher probability of being admitted to an ICU (6). In Peru it has been determined that the incident rate is 10 times higher in adults than in children (7) and COVID-19 behavior is unknown in pediatric patients with and without comorbidities.

Peruvian health systems consist of the public and private system, the INSN-SB is a public center that takes care of pediatric patients who have been referred from another national hospital in their majority. Most of our patients are registered in the “Sistema Integral de Salud” (SIS) which is the public insurance created firstly as a partial financing program and to date it has universal coverage for any person who resides in Peru (8).

The aim of the study is to describe the clinic-epidemiological and treatment characteristics of COVID-19 diagnosed children hospitalized in the INSN-SB which characterizes for being a specialized surgery center of high complexity.

Methods

Site and study design

The INSN-SB is a surgical and specialized pediatric hospital of high complexity of national reference that attends mainly patients with cardiovascular surgical pathology, neurosurgery as well as patients with onco-hematologic disease and organ transplant.

The INSN-SB has 306 beds from which 24 beds are patients with confirmed COVID-19 diagnosis, 25 beds for suspicious cases and 12 beds for PICU.

A retrospective study reviewing clinical histories of patients with confirmed COVID-19 diagnostic, during March to July 2020 was performed.

Participants

Hospitalized patients who are younger than 18 years old with confirmed COVID-19 diagnosis were included through serological and molecular tests. Additionally, patients with incomplete data from the clinical history were not included.

For laboratory diagnosis of SARS-CoV-2 infection, tests based on lateral flow immunochromatography and/or molecular tests using nasopharyngeal swabs for polymerase chain reactions (PCR) were performed. Immunochromatography tests were performed and processed in our institution, on the other hand molecular tests samples were taken in our institute but processed in the National health Institute (INS). Moreover, laboratory confirmatory tests were performed in asymptomatic patients previous to chemotherapy or in the surgery perioperative (emergency or elective). Image tests were prescribed by a pediatric doctor and were performed following the guidelines for attendance of COVID-19 patients of the INSN-SB (Figure 1).

Variables of interest

COVID-19 cases definition was considered according to the institutional norm of the Peruvian Ministry of health (MINSa) (9), as well as the WHO (World Health Organization) definition of MIS-C which includes children and adolescents between 0 and 19 years old (10).

Evaluated epidemiological variables were sex, age, city of origin, weight, height, comorbidity and direct contact with SARS CoV-2 infected patients. The clinical variables included were: date of symptoms onset and the presence or absence of symptoms like general discomfort, cough, shortness of breath, diarrhea, abdominal pain, nausea, vomit, headache, rhinorrhea and pharyngeal pain. Clinical signs considered were: fever, conjunctival injection, rash, dyspnea, rhonchus, wheezing, crepitant, sub crepitant, convulsions, pharyngeal exudate, pretibial edema or limb peeling and strawberry tongue.

Laboratory tests for SARS CoV-2 infection were both rapid and molecular tests. Furthermore, laboratory test like: hemoglobin, leukocytes, white blood cell differential, platelets, albumin, creatinine, ferritin, C reactive protein (CRP), procalcitonin, erythrocyte sedimentation rate (ESR), lactic dehydrogenase (LDH), hepatic profile, prothrombin time (PT), D-dimer, creatine phosphokinase (CPK), creatine phosphokinase-MB (CPK-MB) and lactic acid were included.

As microbiological variables, IgM antibodies for *Mycoplasma pneumoniae*, Cytomegalovirus, Epstein-Barr virus, influenza A and B, herpes 1 and parvovirus B19 were requested. Additionally, blood cultures were performed. Furthermore, radiology patterns in thorax radiology were described.

Treatment received during COVID-19 infection was described based on groups of drugs. (antibiotics, antifungal, antiviral, antiparasitic, anticoagulant, antipyretic, human immunoglobulin, corticosteroids and vasoactive substances).

Finally, clinical picture severity, PICU requirement and date of admission were evaluated. In addition, MIS-C presence or absence, as well as hospital stay considering final patient condition and the cut-off point as the last day of July 2020.

Data analysis

The study data were collected and administered using the Integrated Hospital Management System (SIS Galen Plus) (11) and the electronic data capture tools REDCap (12,13) housed in the INSN-SB.

The statistical analysis used the STATA version 16 program (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC). In the first place, descriptive statistics of the variables of interest were performed, where the quantitative variables were represented by the median and the interquartile range, due to the non-normal distribution of the values, and the qualitative variables were analyzed using frequency tables.

Ethical aspects

The present study was approved by the Institutional ethics committee in research of the INSN-SB with the research code PI-429.

Patient and Public Involvement

The patients were not involved in the development of the research question and outcome measures.

Results

Between March and July 2020, 576 of patients were admitted to the INSN-SB with COVID-19 suspicion, from which the 19.9% (n=115) had confirmed diagnosis by molecular or quick tests. A total of 91 patients were analyzed. Most patients were male, the prevalent age group was schoolchildren with a median of 4 years old (1-8). Only 2 neonates patients were reported, 61.5% (n=56) of patients originated from Lima and most of them 89.1% (n=81) had incomplete vaccines. From patients that needed a surgical procedure, 53.8% were an emergency.

Comorbidities were present in 53.8% (n=49) of patients, being cardiovascular and neurological the most frequent.

Admitted to PICU were 22 patients, mostly male (54.5%) with an age median of 2.5 years old (1-9). No patient presented complete vaccines and the majority (66.7%) were subject to elective surgery. It was not possible to determine if patients had a known contact with COVID-19 carriers in 81.8% of the cases. Underlying comorbidities were found in 68.2% of patients (Table 6). Regarding imaging studies, 61.9% (n=13) of patients presented abnormal thorax radiography. Deceased patients represented 27.3% (n=6/22).

The reported symptomatology was: general discomfort 23.1% (n=21), cough 19.8% (n=18), shortness of breath 14.3% (n=13), vomiting 12.1% (n=11). Moreover, as evident signs patients reported: fever 39.6% (n=36), dyspnea 13.2% (n=12), rhonchus 9.9% (n=9) and convulsions 5.5% (n=5).

Overall, most patients had a normal thorax radiography 63.6% (n=14). Additionally, the most frequent thorax radiology pattern was the bilateral interstitial 57.37% (n=15).

With regards to the 9 deceased patients, 4 had a positive molecular test and 5 had a positive quick test, age range median was 5 years old (1-12), 88.9% (8/9) of patients presented comorbidities, 1 patient presented both cardiovascular and neurological comorbidities, 2 cardiological, 2 oncological, 1 hematological, 1 gastrointestinal and 1 with a skin burn comorbidity.

In relation to MIS-C, only 6.6% (n=6) of patients presented the criteria exposed by the WHO, of which the majority did not require PICU admission (n=4).

Results from patients who had laboratory tests on admission, showed that the main alterations were the C-reactive protein (CRP) levels with 9.4 mg/L (1.1-96.7) and D-dimer with 0.68 ug/ml (0.27-1.65). There was no sign of greater alteration of procalcitonin with 0.14 (0.005-0.365) nor in the aspartate transaminase (AST), alanine transaminase (ALT) and creatinine levels. Concerning the hemogram, most of our patients were not anemic, hemoglobin 11.8 g/dl (9.8-12.8). No leukocytosis, neutrophilia, left deviation or pronounced lymphocytopenia (leukocytes in 10^8 x 10^3 /uL (7430-1450), lymphocytes 3040×10^3 /uL (1820 -4910), neutrophils 5045×10^3 /uL (3095 – 9240)) (Table 3) were found.

Mycoplasma pneumoniae was the most isolated microorganism with 9.9% (n=9) by IgM serology, followed by Cytomegalovirus with 3.3% (n=3), Epstein-Barr virus with 2.2% (n=2) and Influenza with 1.1% (n=1). By means of blood culture, the most abundant microorganism isolated were Gram positives with 42.9% (n=9) and in less proportion Gram negatives with 38.1% (n=8) and fungus with 19% (n=4).

In regard to the drugs administered for other pathologies, 76.9% (n=70) of patients received antibiotics from which the most prescribed were cephalosporins with 58.6%

(n=41) and glycopeptides with 40% (n=28). Moreover, it is important to mention that 40% (n=25) of patients received carbapenem. Macrolides like azithromycin was used in 17.14% (n=12) of the cases. Concerning antifungals, most patients received therapy with azoles 87.50% (n=7). Antiparasitic were prescribed for 25.3% (n=23) of patients and hydroxychloroquine represented the 17.4% (n=4) of these prescriptions. Additionally, antipyretics were used in 89% (n=81) of patients from which the majority received paracetamol, an 18.7% (n=17) of patients received anticoagulants, 31.9% (n=29) received corticosteroid and the 28.6% (n=26) vasoactive. With reference to MIS-C, the 5.5% (n=5) of patients received human immunoglobulin (Table 4).

Discussion

In this study, it was found that the majority of patients presented a mild clinic picture and almost a third of patients were admitted to PICU in an associated comorbidity context. In addition, a group of patients were described with diagnostic criteria of MIS-C from which all of them evolved in a favorable manner.

Similar to the findings reported in our study, the Center for Disease Control and Prevention found that from 576 hospitalized children the median age was 8 years old (14) and in a systematic review the age mean was 8.9 years old (15) and males were predominant (14,15). Furthermore, only a third of patients presented family contact (26.4%), in contrast with other studies where they showed family contact as a background in more than 40% of cases (15,16), this finding can be explained due to the lack of information about diagnosis in the family surroundings.

Even though in this study respiratory symptoms and fever were the most frequent clinical manifestations, 33% of patients presented gastrointestinal symptoms. In literature gastrointestinal manifestations are irregular and nowadays it is described in 20% of the cases (6, 14, 17). Similar to other studies, the frequent coinfection was with

Mycoplasma pneumoniae and in less proportion with other respiratory viruses (15, 18, 19). In relation to that, it was described that viral respiratory infections could predispose the development of over-aggregated bacterial infections like infections with *M. pneumoniae* due to the alteration of respiratory mucociliary clearance and the immune system response (20). Nevertheless, *M. pneumoniae* infection could also precede viral infection (21).

Comparable to our findings, it has been reported in other studies that the most frequent comorbidities were neurological with 11% (65/614) and hemato-oncological 8% (45/614) (6). Nevertheless, another study found the most frequent comorbidities asthma (12.3%), followed by anemia of sickle cells (7%) (20). Many of these comorbidities are related to congenital pathologies unlike adults. Regarding the severity of the disease, in this study 68.2% of PICU patients presented a comorbidity which is a high percentage which relates with other studies that report more than 80% of ICU patients hospitalized with comorbidities (4).

An increase of CPR and Dimer-D was fundamentally observed in this study. In accordance to findings in literature, a variety of laboratory alterations have been described in COVID-19, especially in inflammatory serum markers (6, 15, 23, 24) a study found high levels of CPR, procalcitonin, interleukin-6, ferritin and Dimer-D in relation to severity (23). Our findings could have been explained by the elevated proportion of patients with mild symptoms, moderate and because only initial tests were included in the analysis.

In relation to MIS-C cases, 6 patients with MIS-C diagnostic were found and 2 required PICU admission similar to what was described in another Peruvian report ($\frac{1}{8}$) (24). Meanwhile, in another study MIS-C cases represented 5 time more probabilities of PICU admission, however, no MIS-C patient died (6). In both studies all patients had a

favorable evolution. In comparison, in a MIS-C systematic review in children and adolescents, it was described that MIS-C seems to be a condition of major severity with 38% (531/783) of cases requiring PICU admission (25).

Antibiotics prescription was high despite few microbiological findings. In the literature, a meta-analysis described in both adults and children that 71.3% had antibiotic prescription even though bacterial coinfection prevalence and COVID-19 was low and secondary bacterial coinfection in patients was 14% (26). These results suggest that antibiotics should be prescribed under a clear clinical suspicion of bacterial infection in patients with COVID-19.

In this study, hydroxychloroquine was less used and immunoglobulin use was reserved fundamentally for patients with MIS-C criteria. Moreover, in a systematic review 7.8% of children received hydroxychloroquine, 4.1% corticosteroids and 3.1% immunoglobulin (15). Regarding hydroxychloroquine, the limited scientific evidence reported initially can explain the findings in comparison to intravenous immunoglobulin which is accepted as immunomodulatory therapy in the management of Kawasaki and MIS-C (6, 24, 27, 28).

This study has some limitations, observational retrospective information was presented. A limitation was the absence of complete baseline tests proposed for COVID-19, partly explained by the diversity of clinical criteria for the request. Finally, for the diagnosis of MIS-C, not all patients underwent a serological test for SARS-CoV 2, and in the present study, only those who had a positive confirmatory test were included.

As a conclusion, SARS CoV-2 infection in children presents mild and moderate clinical manifestations. A great proportion of patients presented comorbidities, being higher in PICU admitted and deceased patients.

Acknowledgment

We would like to thank all services and offices of the INSN-SB for the support and facilities provided during the development of this study.

References

1. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr.* 2020;109(6):1088-95.
2. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics* Jun. 2020;145(6):e20200702.
3. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al. Prevalence and severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *Journal of Clinical Virology.* 2020;127:104371.
4. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatrics.* 2020.
5. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. *The Lancet Infectious diseases.* 2020:S1473-3099(20)30651-4.
6. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. 2020;370:m3249.
7. MINSA. Situación actual : Brote de COVID-19 en Perú 2020 [Available from: https://www.dge.gob.pe/portal/index.php?option=com_content&view=article&id=678].
8. Lazo-Gonzales O, Alcalde-Rabanal J, Espinosa-Henao O. El sistema de salud en Perú: situación y desafíos. Lima: Colegio Médico del Perú. 2016.
9. Alerta Epidemiológica Código: AE-019-2020 [Internet]. 2020. Available from: <https://www.dge.gob.pe/portal/docs/alertas/2020/AE019.pdf>.
10. WHO. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 - Scientific Brief 2020 [Available from:

<https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>.

11. UNMSM. Gestión en Salud: SIS-GalenPlus 2020 [Available from: <http://gestionensalud.medicina.unmsm.edu.pe/?tool=sis-galenplus>].
12. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Informatics*. 2009;42(2):377-81.
13. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *Journal of Biomedical Informatics*. 2019;95:103208.
14. Kim L WM, O'Halloran A, et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States. *MMWR Morb Mortal Wkly Rep*. March 1–July 25, 2020;1081–1088.
15. Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: A systematic review. *EClinicalMedicine*. 2020;24:100433.
16. Fang F, Luo XP. [Facing the pandemic of 2019 novel coronavirus infections: the pediatric perspectives]. *Zhonghua Er Ke Za Zhi*. 2020;58(2):81-5.
17. Götzinger F, Santiago-García B, Noguera-Julián A, Lanasa M, Lancella L, Calò Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health*. 2020;4(9):653-61.
18. Zhang C, Gu J, Chen Q, Deng N, Li J, Huang L, et al. Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series. *PLOS Medicine*. 2020;17(6):e1003130.
19. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and Other Clinical Characteristics of COVID-19 in Children. *Pediatrics*. 2020;146(1).
20. Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. 2017;8(1041).
21. Chiu C-Y, Chen C-J, Wong K-S, Tsai M-H, Chiu C-H, Huang Y-C. Impact of bacterial and viral coinfection on mycoplasmal pneumonia in childhood community-acquired pneumonia. *Journal of Microbiology, Immunology and Infection*. 2015;48(1):51-6.

22. Foster CE, Moulton EA, Munoz FM, Hulten KG, Versalovic J, Dunn J, et al. Coronavirus Disease 2019 in Children Cared for at Texas Children's Hospital: Initial Clinical Characteristics and Outcomes. *Journal of the Pediatric Infectious Diseases Society*. 2020;9(3):373-7.
23. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York. *JAMA pediatrics*. 2020:e202430-e.
24. De Coll-Vela LE, Zamudio-Aquise MK, Nuñez-Paucar H, Bernal-Mancilla RR, Schult-Montoya SC, Ccorahua-De La Paz M, et al. Síndrome inflamatorio multisistémico asociado a COVID-19 en niños: serie de casos en un hospital pediátrico de Perú. 2020. 2020.
25. Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. *Paediatric Respiratory Reviews*. 2020.
26. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2020.
27. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. 2004;114(6):1708-33.
28. Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. 2020;79(8):999-1006.

Tables

Table 1. Demographic characteristics of COVID-19 patients treated in the INSN-SB (n=91).			
Characteristics		Total	
		n	%
Sex			
	Feminine	33	36,3
	Masculine	58	63,7
Age (years)		4 (1-8)	
Origin			
	Lima	56	61,5
	Province	35	38,5
Incomplete vaccination		81	89,1
Admitted due to surgery			
	Emergency	21	53,8
	Elective	18	46,2
Contact			
	Family	24	26,4
	Patient	4	4,4
	Unknown	63	69,2
Diagnostic test			
	Quick test	45	49,4
	Molecular test	46	50,6
Radiography			
	Normal	45	63,4
	Abnormal	26	36,6
Comorbidity presence			
	Yes	49	53,8

	No	42	46,2
MIS-C presence			
	Yes	6	6.6
	No	85	93.4
Final patient's state			
	Survivor	82	90.1
	Non-survivor	9	9.9
*Median IQR			

Table 2. Clinical and radiological characteristics of COVID-19 patients treated in the INSN-SB (n=91).

Characteristics	Total	
	n	%
Symptoms		
General discomfort	21	23,1
Cough	18	19,8
Shortness of breath	13	14,3
Vomit	11	11,2
Abdominal pain	10	11,0
Rhinorrhea	8	8,8
Nausea	6	6,6
Diarrhea	3	3,3
Pharyngeal pain	3	3,3
Convulsions	2	2,2
Headaches	2	2,2
Signs		
Fever (Temp in °C)	36	39,6
Dyspnea	12	13,2
Rhonchus	9	9,9
Wheezing	5	5,5
Convulsions	5	5,5
Crackles	4	4,4
Lymphadenopathy	4	4,4
Rash	3	3,3
Pretibial edema	2	2,2
Strawberry tongue	1	1,1
Conjunctival injection	1	1,1

Radiological thorax pattern			
	Bilateral interstitial	15	57,7
	Unilateral alveolar	8	30,7
	Unilateral interstitial	3	11,5
	Bilateral alveolar	2	7,6

Table 3. Laboratorial and microbiological characteristic of COVID-19 patients treated in the INSN-SB

Characteristics	Median	Interquartile range
Hematology		
Hemoglobin (g/dL)	11,8	9,8-12,8
Leukocytes (10^3 /uL)	10,8	7,43-14,57
Lymphocytes (10^3 /uL)	3,04	1,82 – 4,91
Monocytes (10^3 /uL)	0,63	0,45 – 0,96
Neutrophils (10^3 /uL)	5,05	3, 10-9,24
Band neutrophils (10^3 /uL)	0	0,0
Platelets (10^3 /uL)	314	233,0-399,5
Biochemistry		
C-Reactive protein (mg/L)	9,4	2,1-96,7
Erythrocyte sedimentation rate (mm/h)	28	15-50
Creatinine (mg/dL)	0,33	0,22-0,45
Albumin (g/dL)	4,01	3,49-4,5
Aspartate transaminase (AST) (U/L)	31	22-43
Alanine transaminase (ALT) (U/L)	17	13-32
Ferritin (ng/dL)	276,10	93,8-468,1
Total bilirubin (mg/dL)	0,62	0,34-1,22
Prothrombin time (sec)	14,8	13,7-16,2
Fibrinogen (mg/dL)	344,5	266-502
D-dimer (ug/mL)	0,69	0,27-1,65
Procalcitonin (ng/mL)	0,14	0,05-0,65
Creatine phosphokinase (CPK) (U/L)	110	40-254
CPK-MB (U/L)	29.9	24,5-38
Lactic acid (mmol/L)	2	1,4-3,4
Lactic dehydrogenase (LDH) (U/L)	650	442-848

Serology	n	%
<i>Mycoplasma</i>	9	9,9
Cytomegalovirus	3	3,3
Epstein-Barr virus	2	2,2
Influenza B	1	1,1
Herpes 1	1	1,1
Parvovirus B19	1	1,1
Gram staining	n=21	%
Gram positives	9	42,9
Gram negatives	8	38,1
Fungus	4	19,0

Table 04: Frequency of prescription in patients with COVID-19 treated in the INSN SB (n=91)

Drug prescriptions	Total	
	n	%
Antibiotics	70	76,9
Cephalosporins	41	58,57
Glycopeptide	28	40
Carbapenems	25	35,71
Penicillin + β -Lactamase inhibitor	14	20
Macrolides	12	17,14
Aminoglycoside	9	12,86
Lincosamides	9	12,86
Penicillin	8	11,43
Sulfonamides	7	10
Quinolones	3	4,29
Oxazolidinones	1	1,43
Nitrofurantoin	1	1,43
Antifungals	8	8,8
Azoles	7	87,5
Echinocandin	1	12,5
Antivirals	1	1,1
Nucleoside analogues (acyclovir)	1	100
Antiparasitic	23	25,3
Nitroimidazole	20	86,96
4-Aminoquinoline (hydroxychloroquine)	4	17,39
Benzimidazole	1	4,35
Anticoagulants	17	18,7
Low-molecular-weight heparin- Enoxaparin	12	71

	Others	8	47
Antipyretics		81	89
	Pyrazolone	65	80,25
	para aminophenol	57	70,37
Human immunoglobulin		5	5,5
Corticosteroids		29	31,8
Vasoactive		26	28,6

Table N°5: Comorbidities of patients with COVID-19 treated in the INSN-SB (n=91)		
Comorbidities	Total	
	n	%
Presence of comorbidity		
Yes	49	53,8
No	42	46,2
Type of comorbidity		
Neurologic	15	31,2
Cardiologic	12	25,5
Hematologic	7	14,9
Oncologic	7	14,9
Gastrointestinal	6	12,2
Trauma	4	7,7
Respiratory	4	7,7
Burns	3	5,77
Others	2	3,8

Table 06.			
Demographic characteristics of the PICU patients with COVID-19 treated in the INSN-SB (n=22)			
Characteristics		PICU	
		n	%
Sex			
	Female	10	45,5
	Male	12	54,5
Age (years)		2.5 (1-9)	
Region			
	Lima	11	50
	Province	11	50
Incomplete vaccination		22	100
Admission due to surgery			
	Emergency	3	33,3
	Elective	6	66,7
Contact			
	Family	3	13,6
	Patient	1	4,6
	Unknown	18	81,8
Diagnostic test			
	Immunochromatography	8	36,4
	Molecular assay	14	63,6
Radiography			
	Normal	8	38,1
	Abnormal	13	61,9
Comorbidity			
	Yes	15	68,2
	No	7	31,8

Presence of MIS-C			
Yes		2	9,1
No		20	90,9
Final state			
Survivor		16	72,7
Non-survivor		6	27,3
*Median, IQR			

Figure 1. Flow diagram of the selection of patients with COVID-19 in the Instituto

Nacional de Salud del Niño San Borja during the period from March 1st to July

31st, 2020.

